News and Trends 29 Jul 2016
Gene Therapy for severe Hemophilia has new Phase I/II Results
uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia B, a rare genetic disorder. After 9 months, the therapy maintains 75% reduction of transfusions. A good sign for the therapy’s durability. Although quite rare (1 in 20,000 male births), Hemophilia B is famous for being spread in European royal […]